Trade

with

KYTHERA Biopharmaceuticals Inc
(NASDAQ: KYTH)
AdChoices
34.14
+0.85
+2.55%
After Hours :
34.14
0.00
0.00%

Open

33.34

Previous Close

33.29

Volume (Avg)

200.26k (154.81k)

Day's Range

33.20-34.23

52Wk Range

29.50-56.36

Market Cap.

754.78M

Dividend Rate ( Yield )

-

Beta

-

Shares Outstanding

22.67M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Drug Manufacturers – Major
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 0

    • Net Income

    • -51.91M

    • Market Cap.

    • 754.78M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • -

    • Forward P/E

    • -

    • Price/Sales

    • -

    • Price/Book Value

    • 7.59

    • Price/Cash flow

    • -13.66

      • EBITDA

      • -49.71M

      • Return on Capital %

      • -106.40

      • Return on Equity %

      • -157.48

      • Return on Assets %

      • -106.40

      • Book Value/Share

      • 4.39

      • Shares Outstanding

      • 22.67M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • -

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 0.89

          • Net Income

            YTD/YTD (last year)

          • -

          • 7.80

          • Net Income

            Q/Q (last year)

          • -

          • 4.50

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 6.10

          • Net Income

            5-Year Annual Average

          • -

          • 3.73

          • Dividends

            5-Year Annual Average

          • -

          • 2.17

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -

            • 69.92

            • Pre-Tax Margin

            • -

            • 21.84

            • Net Profit Margin

            • -

            • 18.37

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 71.90

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 21.92

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 903.40B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.25

              • 0.32

              • Current Ratio

              • 9.80

              • 1.92

              • Quick Ratio

              • 9.64

              • 1.31

              • Interest Coverage

              • -38.56

              • 17.64

              • Leverage Ratio

              • 1.39

              • 2.03

              • Book Value/Share

              • 4.39

              • 14.72

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -5.94

                • 22.12

                • P/E Ratio 5-Year High

                • -10.38

                • 193.96

                • P/E Ratio 5-Year Low

                • -2.59

                • 87.26

                • Price/Sales Ratio

                • -

                • 3.75

                • Price/Book Value

                • 7.35

                • 3.75

                • Price/Cash Flow Ratio

                • -13.66

                • 14.03

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -157.48

                    (-)

                  • 17.42

                    (18.66)

                  • Return on Assets %

                    (5-Year Average)

                  • -106.40

                    (-)

                  • 8.45

                    (8.77)

                  • Return on Capital %

                    (5-Year Average)

                  • -117.67

                    (-)

                  • 12.41

                    (13.18)

                  • Income/Employee

                  • -

                  • 90.07k

                  • Inventory Turnover

                  • -

                  • 2.46

                  • Asset Turnover

                  • -

                  • 0.46

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -50.07M
                  Operating Margin
                  -
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -13.66
                  Ownership

                  Institutional Ownership

                  -

                  Top 10 Institutions

                  64.18%

                  Mutual Fund Ownership

                  48.37%

                  Float

                  76.79%

                  5% / Insider Ownership

                  2.47%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    1,304,079

                  • 0.00

                  • 5.75

                  • Fidelity® OTC Portfolio

                  •  

                    1,257,482

                  • 0.00

                  • 5.55

                  • Prudential Jennison Small Company

                  •  

                    786,662

                  • 0.00

                  • 3.47

                  • VA CollegeAmerica Small Cap World

                  •  

                    547,300

                  • 0.00

                  • 2.41

                  • MFS® New Discovery Fund

                  •  

                    480,642

                  • 0.12

                  • 2.12

                  • SPDR® S&P Biotech ETF

                  •  

                    474,958

                  • 3.59

                  • 2.07

                  • Polar Capital Healthcare Opps

                  •  

                    460,000

                  • 0.00

                  • 2.03

                  • Waddell & Reed Advisor Accumulative Fund

                  •  

                    360,000

                  • 4.35

                  • 1.59

                  • iShares Nasdaq Biotechnology

                  •  

                    300,996

                  • -0.69

                  • 1.31

                  • iShares Russell 2000 (AU)

                  •  

                    270,910

                  • -1.01

                  • 1.18

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity Management and Research Company

                  •  

                    3,380,880

                  • +3.55%

                  • 14.91

                  • ARCH Venture Partners

                  •  

                    2,105,740

                  • 0.00%

                  • 9.68

                  • Prospect Management Co. III, LLC

                  •  

                    1,914,566

                  • 0.00%

                  • 8.80

                  • Jennison Associates LLC

                  •  

                    1,894,903

                  • +24.03%

                  • 8.36

                  • Partner Fund Management LP

                  •  

                    952,715

                  • -5.06%

                  • 4.20

                  • Palo Alto Investors, LLC

                  •  

                    949,959

                  • -47.53%

                  • 4.19

                  • MFS Investment Management K.K.

                  •  

                    882,853

                  • +9.22%

                  • 3.89

                  • BlackRock Fund Advisors

                  •  

                    854,064

                  • +21.12%

                  • 3.77

                  • Waddell & Reed Investment Management Co

                  •  

                    745,212

                  • -21.15%

                  • 3.29

                  • Adage Capital Partners Gp LLC

                  •  

                    700,000

                  • -11.86%

                  • 3.09

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Drug Manufacturers – Major

                  Type

                  Distressed

                  Style

                  Small Growth

                  KYTHERA Biopharmaceuticals, Inc. was incorporated in Delaware in June 2004 under the name Dermion, Inc. It commenced operations in August 2005, and it changed its name to AESTHERx, Inc. In July 2006, it changed its name to KYTHERA Bi...moreopharmaceuticals, Inc. It is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. The Company’s objective is to develop first-in-class, prescription aesthetic products using an approach that relies on the scientific rigor of biotechnology to address unmet needs in the rapidly-growing market for aesthetic medicine. The Company’s initial focus is on the facial aesthetics market, which comprises the majority of the aesthetic medicine market. The Company’s prod...moreuct candidate, ATX-101, is a potential first-in-class, injectable drug in late stage clinical development for the reduction of submental fat, which commonly presents as an undesirable double chin. Based on clinical trials conducted to date, ATX-101 has exhibited significant, meaningful and long-lasting results in the reduction of submental fat.lessless

                  Key People

                  Keith R. Leonard

                  CEO/Director/President/Co-Founder

                  Mr. John W. Smither

                  CFO/Chief Accounting Officer

                  Robert T. Nelsen

                  Director

                  Mr. F. Michael Ball

                  Director

                  Dr. Nathaniel David, PhD

                  Director

                  • KYTHERA Biopharmaceuticals Inc

                  • 27200 West Agoura Road

                  • Calabasas, CA 91301

                  • USA.Map

                  • Phone: +1 818 587-4500

                  • Fax: +1 818 587-4591

                  • kytherabiopharma.com

                  Incorporated

                  2004

                  Employees

                  83

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: